[go: up one dir, main page]

WO2005041985A1 - Polysaccharides de plantes appartenant a la famille des panax pour traiter et prevenir l'obesite - Google Patents

Polysaccharides de plantes appartenant a la famille des panax pour traiter et prevenir l'obesite Download PDF

Info

Publication number
WO2005041985A1
WO2005041985A1 PCT/KR2004/002763 KR2004002763W WO2005041985A1 WO 2005041985 A1 WO2005041985 A1 WO 2005041985A1 KR 2004002763 W KR2004002763 W KR 2004002763W WO 2005041985 A1 WO2005041985 A1 WO 2005041985A1
Authority
WO
WIPO (PCT)
Prior art keywords
polysaccharide
panax
obesity
family
polysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2004/002763
Other languages
English (en)
Inventor
Taehwan Kwak
Tae Cheul Roh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MD Bioalpha Co Ltd
KT&G Co Ltd
Original Assignee
MD Bioalpha Co Ltd
KT&G Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MD Bioalpha Co Ltd, KT&G Co Ltd filed Critical MD Bioalpha Co Ltd
Publication of WO2005041985A1 publication Critical patent/WO2005041985A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

  • the present invention relates to a polysaccharide of plants belonging to the Panax family producing effective treatment and prevention of obesity, a method for extracting the same and a pharmaceutical composition containing the same as an active ingredient, and more specifically to a polysaccharide extracted from plants belonging to the Panax family such as Panax ginseng C.A. Mayer and producing effective treatment and prevention of obesity by lowering of body fat.
  • Obesity is broadly divided into primary obesity (simple obesity) and secondary obesity (symptomatic obesity: morbid obesity).
  • causes of the primary obesity include excessive calorie intake, insufficient energy consumption (lack of physical exercise) and reduction of calorie expenditure (basal metabolism).
  • Most cases that are judged as obesity from clinical point of view are primary obesity.
  • Expression and then progression of primary obesity causes various health hazards.
  • secondary obesity develops due to any underlying diseases.
  • Obesity is a risk factor to health, and is responsible for diseases due to increased load of circulation system (for example, hypertension and coronary disease), diseases due to metabolism disorder (for example, diabetes, hypertriglyceridemia), disorder of the liver or biliary system (for example, cholelithiasis), a lowering of respiratory function, or diseases caused by excessive loading to bones or articular system (for example, degenerative articular diseases), or causes problems such as depression of activity.
  • a large number of methods for preventing and treating obesity have been studied from diverse directions. For example, there have been proposed calorie limiting diet therapy, exercise therapy, surgical therapy and pharmacotheraphy such as use of an anorexigenic agent or energy metabolism promoter, but these methods are not effectively employed due to various reasons.
  • red ginseng prepared by steaming ginseng
  • a product for relieving obesity is developed and commercially available as a product for relieving obesity, and such product exerts indirect obesity prevention efficacy by taking advantage of functions that saponin, one of the constituents of ginseng, inhibits absorption of saccharides and cholesterol in the gastrointestinal tract and at the same time, promotes release of absorbed energy.
  • saponin one of the constituents of ginseng
  • methods of relieving obesity using ginseng polysaccharides have yet to be proposed.
  • dietary control includes control of diet through fasting, and control of diet by use of drugs such as morphine or hormone preparations inducing satiety.
  • cytokines also induces loss of body weight, in such a manner that induction of changes in metabolism, similar to immune reactions against infections, leads to reduction of dietary intake.
  • Hormones such as corticotrophin releasing hormone, cholecystokinin, prostaglandins, glucagons, insulin and corticosteroids, known to inhibit appetite, were known as being induced by pyrogenic materials such as lipopolysaccharide and cytokines.
  • pyrogenic materials such as lipopolysaccharide and cytokines.
  • the present invention has been made in view of the above problems, and it is an object of the present invention to provide a polysaccharide (or polysaccharide fraction) extracted from plants belonging to the Panax family, and capable of being used in treating and preventing obesity by lowering of body fat. It is another object of the present invention to provide a method for extracting such a polysaccharide from plants belonging to the Panax family. It is a further object of the present invention to provide a pharmaceutical composition for treating and preventing obesity containing such a polysaccharide as an active ingredient. It is still further object of the present invention to provide a method for treating and preventing obesity using such a polysaccharide or pharmaceutical composition.
  • the above and other objects can be accomplished by the provision of a polysaccharide that is extracted from plants belonging to the Panax family and can be used for treating and preventing obesity by lowering of body fat.
  • a polysaccharide that is extracted from plants belonging to the Panax family can be used for treating and preventing obesity by lowering of body fat.
  • the polysaccharides extracted from plants belonging to the Panax family in accordance with the present invention lower the amount of body fat without causing significant side effects, and thus can be safely used for treating and preventing obesity.
  • plants belonging to the Panax family mention may be made of Panax ginseng C.A.
  • Panax quinquefolium Panax notoginseng
  • Panax pseudoginseng Panax japonicum
  • Panax vietnamensis Ha et Grushv. and they may be used alone or in any combination thereof.
  • Panax ginseng C.A. Mayer is particularly preferred.
  • Polysaccharides in accordance with the present invention may be obtained from roots, leaves, stems and fruits of plants belonging to the Panax family, respectively, and it is particularly preferably obtained from leaves and stems from an economical point of view.
  • polysaccharides of ginseng roots have a molecular weight distribution of about 6000 to 520,000 Da, and an average molecular weight of around 140,000 Da.
  • polysaccharides of ginseng leaves and stems have a molecular weight distribution of about 6000 to 340,000 Da, and an average molecular weight of around 120,000 Da.
  • Polysaccharides in accordance with the present invention contains 30 to 80% neutral saccharide, 10 to 60% acidic saccharide and 0.01 to 10% protein, and the saccharide composition thereof is made up of rhamnose, fucose, arabinose, xylose, mannose, glucose, galactose, galacturonic acid, glucuronic acid, 3-deoxy-D-manno-2- octulosonic acid (KDO) and 3-deoxy-D-lyxo-2-heptulosaric acid (DHA).
  • Specific contents of the respective saccharides may exhibit slight variation depending on kinds of plants belonging to the Panax family, extraction parts (such as roots, leaves and stems), extraction methods and the like.
  • KDO and DHA are polysaccharides contained only in the leaves and stems of ginseng. Specifically, when ginseng extracts obtained through solvent extraction were dissolved in triple distilled water in the concentration of 1 mg/mL and analyzed, it was confirmed that roots of Panax ginseng C.A. Mayer contain 32.8% neutral saccharide, 57.3% acidic saccharide and 6.4% protein, and leaves and stems thereof contain 68.9% neutral saccharide, 15.9% acidic saccharide, and 8.7% protein.
  • leaves and stems of ginseng contain 51.3%) neutral saccharide, 46.8% acidic saccharide, and 0.1% protein, and the saccharide composition is made up of 5.97% rhamnose, 1.22% fucose, 14.86% arabinose, 0.44% xylose, 1.93% mannose, 3% glucose, 22.7% galactose, 31.4% galacturonic acid, 14.4% glucuronic acid, 1.38% KDO and 1.02% DHA.
  • a method for extracting such polysaccharides from plants belonging to the Panax family is also provided.
  • the method for extracting a polysaccharide in accordance with the present invention comprises: (a) placing roots, leaves, stems and/or fruits of a plant belonging to the Panax family in water, cold precipitating or heating the mixture at pH of 4 to 10 and a temperature of 0 to 180°C for 0.5 to 20 hours, and separating remnants including roots, leaves, stems and/or fruits of the plant to obtain an extract; (b) concentrating the extract, and precipitating and separating polysaccharide using an organic solvent; and (c) removing the organic solvent from the separated polysaccharide to obtain a polysaccharide.
  • step (a) if the reaction pH is outside the above-mentioned range, some polysaccharides may be undesirably altered.
  • reaction temperature is too low, an extraction amount is very small and the process does not smoothly progress. Conversely, if the reaction temperature is too high, some polysaccharides may be undesirably altered. Further, if the reaction time is too short, an extraction amount is very small, while if the reaction time is too long, the process is uneconomical and thus is undesirable.
  • the term "cold precipitation" refers to dipping at a temperature of about 0 to 25°C. There is no particular limit to the used amount of water, but for easy extraction, a 10 to 20-fold excess of water may be used based on the volume of raw materials such as roots of ginseng.
  • the extract is concentrated for effective recovery of polysaccharides, and for example, the extract may be concentrated by heating it to a range of 20 to 90°C under reduced pressure between vacuum and 760 mmHg until it reached more than 20 brix, as determined by a saccharometer.
  • an organic solvent 0.1 to IM sodium chloride and lower alcohols or acetone are preferably used.
  • the organic solvent is used in a 1 to 5-fold, preferably 2 to 4-fold excess amount based on the extract volume.
  • the lower alcohols alcohols containing up to 5 carbon atoms such as methanol, ethanol, propanol, butanol and pentanol may be used and ethanol is preferably used.
  • Separation of polysaccharides in step (b) and/or step(c) may be performed by various methods such as filtration (including ultrafiltration), centrifugation, ion exchange resins, adsorption resins and dialysis, and there is no particular limit to separation methods as long as they can separate polysaccharides in accordance with the present invention. Furthermore, such separation processes may be performed by repetition of various methods. An example of more effective separation (purification) method will be described below.
  • the pH of the extract obtained in step (a) was adjusted to about 8.0, 0.4M NaCl/lOmM Tris-HCl was added and passed through an anion exchange resin column at a rate of 30 mL/min.
  • This anion exchange resin was previously equilibrated with 0.4M NaCl/lOmM Tris-HCl so as to adsorb only pigments or impurities and prevent polysaccharides in a sample from adsorbing.
  • This anion exchange resin column was sufficiently washed with a buffer, pH of the passed liquid was adjusted to a range of about 6 to 7 and then passed through an adsorbent resin column at a rate of 30 to 50 mL/min. The column was sufficiently washed with distilled water, and a 3 -fold ethanol precipitation method was used to confirm that all of the sample had passed through the column. About a 3 -fold excess of ethanol (95%) was added to the passed liquid so as to precipitate polysaccharides.
  • step (c) after removing an organic solvent, a drying process may be performed to obtain polysaccharides in the form of powder.
  • the drying process may be performed using hot air, drying under vacuum, lyophilization and spray drying.
  • a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned polysaccharides as an active ingredient, and a pharmaceutically acceptable carrier, and more specifically a composition for treating and preventing obesity.
  • the polysaccharides may be formulated in various pharmaceutical dosage forms depending on desired purpose.
  • an active ingredient specifically polysaccharide of plants belonging to the Panax family is mixed with a variety of pharmaceutically acceptable carriers that can be selected depending on formulation to be prepared.
  • the active ingredient may be, depending on desired purpose, formulated into injectable preparations, transdermal preparations or oral preparations and for easy administration and uniform dose, it is preferably prepared in a unit dosage form.
  • a conventional pharmaceutically acceptable carrier may be used.
  • solution preparations for oral administration such as suspensions, syrups, elixirs and solutions, water, glycol, oil and alcohol may be used as the carrier.
  • solid forms of preparations such as powders, pills, capsules and tablets
  • starch, sugar, kaoline, lubricant, binding agent and disintegrant may be used as the carrier.
  • the most convenient dosage forms are tablets and capsules, and tablets and pills are preferably prepared in enteric coating.
  • an acid scavenger may be used or solid preparations for oral administration such as tablets may be formulated into the enteric film coated preparation and then administered.
  • sterilized water is conventionally used as the carrier, and other ingredients such as dissolution aids can be included.
  • Injectable preparations for example aqueous or oily suspensions for sterile injection may be prepared using suitable dispersants, wetting agents or suspending agents by known techniques.
  • Solvents used herein may include water, Ringer's solution and isotonic NaCl solution, and sterile fixed oil is also conventionally used as the solvent or suspending medium. Any non-irritable fixed oil including mono- and di-glyceride may be used for such purpose and further, fatty acids such as oleic acid may be used in the injectable preparation.
  • penetration promoters and/or suitable wetting agents as the carrier may be optionally used in combination with a suitable additive that is non-irritable to skin.
  • the additive is selected from those that promote administration through skin and/or assist in preparing a desired composition.
  • Transdermal preparation may be administered in various manners such as transdermal patches, creams or ointments.
  • the composition in accordance with the present invention may be formulated into sustained-release preparations.
  • usable carriers include implants, microencapsulated delivery systems, and biodegradable/biocompatible polymers, which are known in the art.
  • therapeutically effective amount means an amount of active ingredient effective to alleviate or reduce symptoms of a disease in need of treatment, or to reduce or retard initiation of clinical markers or symptoms of a disease in need of prevention.
  • the therapeutically effective amount may be empirically determined by experimenting with the above-mentioned polysaccharides in known in vivo and in vitro model systems for a disease in need of treatment.
  • a dose of the active ingredient i.e., polysaccharide of plants belonging to the Panax family is appropriately determined depending on absorptivity, inactivation and excretion rate of the active ingredient in the body, age, sex and conditions of patients.
  • the active ingredient may be administered in an amount of 100 ⁇ g to 6000 mg/day, and preferably 20 to 5000 mg/day, for adults.
  • the pharmaceutical composition in accordance with the present invention may further include other ingredients that do not inhibit action of the active ingredient or assist action of the active ingredient, and may be formulated into various forms known in the art.
  • a method for treating or preventing a disease caused by obesity using a polysaccharide of plants belonging to the Panax family as an active ingredient.
  • obesity-causing diseases include primary obesity as obesity itself and secondary obesity, diseases due to increased load to circulation system (for example, hypertension, coronary disease), diseases due to metabolism disorder (for example, diabetes, hypertriglyceridemia), disorder of the liver or biliary system (for example, cholelithiasis), a lowering of respiratory function, diseases caused by excessive loading to bones or articular system (for example, degenerative articular diseases) and the like. Therefore, administration of the therapeutically effective amount of the polysaccharide of plants belonging to the Panax family in accordance with the present invention to humans lowers body fat, thereby effective for treating and preventing diseases due to obesity.
  • diseases due to increased load to circulation system for example, hypertension, coronary disease
  • diseases due to metabolism disorder for example, diabetes, hypertriglyceridemia
  • disorder of the liver or biliary system for example, cholelithiasis
  • a lowering of respiratory function diseases caused by excessive loading to bones or articular system
  • treating means stopping or retarding progresses of a disease when used in a subject exhibiting onset of the disease
  • preventing means stopping or retarding symptoms of disease development when used in a subject who does not exhibit onset of disease but is at a high risk for such disease onset.
  • Figs. 1 through 4 are, respectively, graphs showing changes in body weight with respect to the passage of time, in a mouse group to which a polysaccharide of Panax ginseng C.A. Mayer in accordance with the present invention was administered and a mouse group to which no polysaccharide of Panax ginseng C.A. Mayer was administered, based on the experimental results of Examples 1 through 4.
  • Preparation Example 1 Preparation of crude polysaccharide extract of ginseng root 100 g of roots of Panax ginseng C.A. Mayer was placed in 1 L of water and heated to extract at 100°C for 5 hours. The extract thus obtained and ginseng roots were separated using an unwoven fabric, centrifuged at 7,000 rpm for 30 min to remove insoluble foreign materials, and the resulting supernatant containing polysaccharides was concentrated at 760 mmHg and 70°C to 20 brix so as to obtain 100 mL of concentrate. Sodium chloride was dissolved in the concentrate thus obtained to IM concentration, 300 mL of ethanol was added and mixed, the mixture was allowed to stand for 1 hour to separate supernatant and precipitate.
  • Preparation Example 2 Preparation of crude polysaccharide of ginseng root Crude polysaccharide of ginseng leaves was obtained using the same procedure as Preparation Example 1, except that leaves of Panax ginseng C.A. Mayer were used instead of roots thereof.
  • Preparation Example 3 Preparation of crude polysaccharide of ginseng stems Crude polysaccharide of ginseng stems was obtained using the same procedure as Preparation Example 1, except that stems of Panax ginseng C.A. Mayer were used instead of roots thereof.
  • Preparation Example 4 Preparation of polysaccharide of ginseng roots 500 g of roots of Panax ginseng C.A. Mayer was crushed with a chopper, and the crushed material was placed in 5 L of distilled water followed by extraction at 4°C for about 15 hours. Gauze was used to separate the extract and sludge, and the extract was centrifuged at 700 rpm for 20 min to recover supernatant.
  • the pH of the supernatant containing polysaccharide was adjusted to about 8.0, 0.5M NaCl/10 rnM Tris-HCl was added and passed through an anion exchange resin (trade name: PA312, a styrene based strong basic anion exchange resin) column at a rate of 30 mL/min.
  • anion exchange resin trade name: PA312, a styrene based strong basic anion exchange resin
  • This anion exchange resin column was sufficiently washed with a buffer, the pH of the passed liquid was adjusted to a range of about 6 to 7 and then passed through an adsorbent resin (trade name: Hp 20, Diaion) column at a rate of 30 to 50 mL/min.
  • the column was sufficiently washed with distilled water, and a 3- fold volume ethanol precipitation method was used to confirm that all of the sample had passed through the column.
  • About a 3 -fold excess of ethanol (95%) was added to the passed liquid so as to precipitate only polysaccharides. This was followed by centrifugation (5000 rpm, 15 min) and dialysis in order to recover polysaccharides.
  • Preparation Example 5 Preparation of polysaccharide of ginseng leaves 500 g of leaves of Panax ginseng C.A. Mayer was placed in 5 L of distilled water followed by extraction with hot water for about 3 hours. Gauze was used to separate the extract and sludge, and the extract was centrifuged at 7000 rpm for 20 min to recover supernatant. The pH of the supernatant was adjusted to about 8.0, 0.4M NaCl/10 mM Tris-HCl was added and passed through an anion exchange resin (trade name: PA312, a styrene based strong basic anion exchange resin) column at a rate of 30 mL/min.
  • anion exchange resin trade name: PA312, a styrene based strong basic anion exchange resin
  • This anion exchange resin was previously equilibrated with 0.4M NaCl/lOmM Tris-HCl so as to adsorb only pigments or impurities and prevent polysaccharides in sample from adsorbing.
  • This anion exchange resin column was sufficiently washed with a buffer, pH of the passed liquid was adjusted to a range of about 6 to 7 and then passed through an adsorbent resin (trade name: Hp 20, Diaion) column at a rate of 30 to 50 mL/min. The column is sufficiently washed with distilled water, and a 3 -fold ethanol precipitation method was used to confirm that all of the sample had passed through the column.
  • Preparation Example 7 Preparation of sample for injectable preparation
  • polysaccharides were passed through a column packed with silica gel, 3 -fold excess of ethanol was added thereto to precipitate polysaccharides followed by centrifugation and recovery, and washed with 2x 95% ethanol to remove impurities.
  • the resulting materials were dissolved in triple distilled water, dialyzed with a molecular weight of 6,000 Da to remove ethanol, passed through a 0.2 ⁇ m filter to prepare a sterile sample containing no pyrogenic materials.
  • a predetermined amount of the sterilized sample was pipetted into a 3 mL vial, frozen and then lyophilized. The dried sample was dissolved in physiological saline to prepare a sample for injection.
  • Example 1 Composition analysis of ginseng extracts obtained in Preparation Examples 1 through 7 was carried out as follows. Quantitative analysis was performed for total saccharide content using galactose as a standard with a phenol-sulfuric acid method (Dubois et al., Anal. Chem., 28, 350, 1956), for acidic saccharide content using ⁇ -D- galacturonic acid as a standard with a m-hydroxybiphenyl method (Blumenkrantz et al., Anal. Biochem., 54, 484, 1973), for protein content using bovine albumin as a standard with a Lowry method (Lowry et al., J.
  • roots of ginseng had a molecular weight distribution of about 6,000 to 520,000 Da and an average molecular weight of about 140,000 Da, while leaves and stems of ginseng had a molecular weight distribution of about 6,000 to 340,000 Da and an average molecular weight of about 120,000 Da
  • Example 2 Experiment on anti-obesity effect of ginseng root polysaccharide An experiment on an anti-obesity effect of crude polysaccharide extracted from ginseng roots was performed in the db/db (10 weeks, male) mouse as the obesity model. Crude polysaccharide of ginseng roots obtained in Preparation Example 1 was dissolved in PBS, sterile filtered through a 0.2 ⁇ m filter, and the resulting sterilized sample was administered to the peritoneal cavity of the db/db mouse, at concentrations of 500 ⁇ g/mouse and 1 mg/mouse (amount of polysaccharide), respectively, every day. Body weight of animals was measured at intervals of 5 days and feed intake was confirmed every day.
  • the db/db normal group which was not administered polysaccharides, showed about 2.7% gain in body weight, while the group in which 500 ⁇ g of polysaccharide of ginseng roots was administered showed 4.2% loss in body weight and the group in which 1 mg of polysaccharide was administered showed 10.5% loss in body weight (see Fig. 1).
  • Example 3 Experiment on anti-obesity effect of ginseng leave polysaccharide An experiment on an anti-obesity effect of crude polysaccharide extracted from ginseng leaves was performed in the db/db (10 weeks, male) mouse as the obesity model. Crude polysaccharide of ginseng roots obtained in Preparation Example 2 was dissolved in PBS, sterile filtered through a 0.2 ⁇ m filter, and the resulting sterilized sample was administered to the peritoneal cavity of the db/db mouse, at concentrations of 200 ⁇ g/mouse and 500 ⁇ g/mouse, respectively, every day. Body weight of animals was measured at intervals of 5 days and feed intake was confirmed every day.
  • the normal group showed about 2.1% gain in body weight
  • the group in which 200 ⁇ g of crude polysaccharide of ginseng leaves was administered showed 5.6% loss in body weight
  • the group in which 500 ⁇ g of crude polysaccharide was administered showed 12.7% loss in body weight (see Fig. 2).
  • the polysaccharide administered group exhibited relatively low dietary intake compared to a control group, at the early stage of administration, but exhibited a dietary intake aspect approaching that of the control group, with respect to the passage of time.
  • Example 4 Experiment on anti-obesity effect of purified ginseng root polysaccharide An experiment on an anti-obesity effect of polysaccharide extracted from ginseng roots was performed in the db/db (10 weeks, male) mouse as the obesity model. Polysaccharide of ginseng roots obtained in Preparation Example 4 was dissolved in PBS, sterile filtered through a 0.2 ⁇ m filter, and the resulting sterilized sample was administered to the peritoneal cavity of the db/db mouse, at concentrations of 200 ⁇ g/mouse and 500 ⁇ g/mouse, respectively, every day. Body weight of animals was measured at intervals of 5 days and feed intake was confirmed every day.
  • the normal group showed about 2.7% gain in body weight
  • the group in which 200 ⁇ g of polysaccharide of ginseng roots was administered showed 3.5% loss in body weight
  • the group in which 500 ⁇ g of polysaccharide was administered showed 8.6% loss in body weight (see Fig. 3).
  • the polysaccharide administered group exhibited relatively low dietary intake compared to a control group, at the early stage of administration, but exhibited a dietary intake aspect approaching that of the control group, with respect to the passage of time.
  • the normal group showed about 2.7% gain in body weight
  • the group in which 200 ⁇ g of polysaccharide of ginseng stems was administered showed 4.2% loss in body weight
  • the group in which 500 ⁇ g of the polysaccharide was administered showed 9.7% loss in body weight (see Fig. 4).
  • the polysaccharide administered group exhibited relatively low dietary intake compared to a control group, at the early stage of administration, but exhibited a dietary intake aspect approaching that of the control group, with respect to time lapse.
  • a polysaccharide in accordance with the present invention can be easily extracted from plants belonging to the Panax family and use of such a polysaccharide as an active ingredient can provide treatment and prevention of obesity.
  • plants belonging to the Panax family have been used as the raw material of medicines for a long period of time, general problems associated with use thereof as medicines, including toxicity can be naturally solved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un polysaccharide de plantes appartenant à la famille des Panax, un procédé d'extraction de celui-ci et une composition pharmaceutique le contenant comme principe actif. Ce polysaccharide, qui peut être extrait facilement de plantes appartenant à la famille des Panax, réduit les taux de graisse corporelle et est très efficace dans le traitement et la prévention de maladies provoquant l'obésité. De plus, l'invention permet de préparer le polysaccharide, lors de son extraction des feuilles ou des tiges de plantes de la famille des Panax, à un coût de production très bas, ce qui est économiquement avantageux. Comme on utilise depuis longtemps les plantes de la famille des Panax comme matière première de médicaments, les problèmes généraux associés à celles-ci, p. ex. toxicité, peuvent être résolus naturellement.
PCT/KR2004/002763 2003-10-31 2004-10-29 Polysaccharides de plantes appartenant a la famille des panax pour traiter et prevenir l'obesite Ceased WO2005041985A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2003-0077082 2003-10-31
KR1020030077082A KR100544052B1 (ko) 2003-10-31 2003-10-31 비만의 치료 및 예방 효능을 지닌 인삼속 식물 다당체

Publications (1)

Publication Number Publication Date
WO2005041985A1 true WO2005041985A1 (fr) 2005-05-12

Family

ID=34545685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/002763 Ceased WO2005041985A1 (fr) 2003-10-31 2004-10-29 Polysaccharides de plantes appartenant a la famille des panax pour traiter et prevenir l'obesite

Country Status (2)

Country Link
KR (1) KR100544052B1 (fr)
WO (1) WO2005041985A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165273A1 (en) * 2008-09-05 2011-07-07 Jiao Guo A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
CN106146685A (zh) * 2016-09-30 2016-11-23 重庆三峡医药高等专科学校 一种莼菜多糖的提取与分离纯化工艺
WO2017023703A1 (fr) * 2015-07-31 2017-02-09 Sivanaray, Inc. Composés, compositions et méthodes pour la prévention ou le traitement du foie et d'affections associées aux lipides
WO2018132745A1 (fr) * 2017-01-13 2018-07-19 Sivanaray Inc. Composés, compositions et méthodes pour la prévention ou le traitement d'affections du foie et d'affections associées aux lipides
WO2018156513A1 (fr) * 2017-02-21 2018-08-30 Sivanaray Inc. Composés, compositions et méthodes pour la prévention ou le traitement d'affections liées au foie, aux lipides et au glucose
CN111533820A (zh) * 2020-05-11 2020-08-14 昆明理工大学 一种三七多糖及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080067747A (ko) * 2007-01-17 2008-07-22 건국대학교 산학협력단 홍삼 박으로부터 산성 다당체를 추출하는 방법
CN115414379B (zh) * 2022-08-17 2023-11-17 广东药科大学 三七多糖sqp20在制备治疗肠损伤与炎性浸润的药物的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NG TB ET AL: "Hypoglycemic constituents of Panax ginseng", GEN.PHARMACOL, vol. 16, no. 6, 1985, pages 549 - 552 *
XIE ET AL: "Ginseng berry reduces blood glucose and body weight in db/db mice", PHYTOMEDICINE, vol. 9, no. 3, 2002, pages 254 - 258 *
YANG ET AL: "Effects of ginseng polysaccharides on reducing glucose and liver glycogen", ZHONGGUO YAO LI XUE BAO, vol. 11, no. 6, 1990, pages 520 - 524 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165273A1 (en) * 2008-09-05 2011-07-07 Jiao Guo A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
US8394431B2 (en) * 2008-09-05 2013-03-12 Jiao Guo Composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
WO2017023703A1 (fr) * 2015-07-31 2017-02-09 Sivanaray, Inc. Composés, compositions et méthodes pour la prévention ou le traitement du foie et d'affections associées aux lipides
US20180256616A1 (en) * 2015-07-31 2018-09-13 Sivanaray, Inc. Compounds, Compositions and Methods for Prevention or Treatment of Liver and Lipid-Related Conditions
CN106146685A (zh) * 2016-09-30 2016-11-23 重庆三峡医药高等专科学校 一种莼菜多糖的提取与分离纯化工艺
WO2018132745A1 (fr) * 2017-01-13 2018-07-19 Sivanaray Inc. Composés, compositions et méthodes pour la prévention ou le traitement d'affections du foie et d'affections associées aux lipides
WO2018156513A1 (fr) * 2017-02-21 2018-08-30 Sivanaray Inc. Composés, compositions et méthodes pour la prévention ou le traitement d'affections liées au foie, aux lipides et au glucose
CN111533820A (zh) * 2020-05-11 2020-08-14 昆明理工大学 一种三七多糖及其制备方法与应用

Also Published As

Publication number Publication date
KR100544052B1 (ko) 2006-01-23
KR20050041802A (ko) 2005-05-04

Similar Documents

Publication Publication Date Title
CA2680078C (fr) Formulations contenant des extraits de cynara scolymus et de phaseolus vulgaris qui sont utiles dans le traitement de l'obesite
JP6483240B2 (ja) 希少ジンセノサイドを高含量で含有する、山参もしくは高麗人参を含む高麗人参類の抽出物または高麗人参類の形成層由来植物幹細胞もしくはその抽出物の製造方法
CA2386215C (fr) Procede de traitement des insuffisances veineuses chroniques a l'aide d'un extrait de feuilles de vigne rouge
CN101596222A (zh) 一种精制银杏叶提取物、粉针及其制备方法
WO1999026643A1 (fr) Methodes de preparation de bioginko
KR100228510B1 (ko) 진세노사이드Ｒｇ3및/또는Ｒｇ5의제조방법
WO2003086440A1 (fr) Nouvelle utilisation de l'extrait de ginseng traite et saponine isolee a partir de ce dernier
JP6346564B2 (ja) チコリ抽出物を含む組成物
WO2005041985A1 (fr) Polysaccharides de plantes appartenant a la famille des panax pour traiter et prevenir l'obesite
JP2002308777A (ja) 血管新生阻害作用を有する組成物
WO2004096240A1 (fr) Anthocyanines utiles au traitement des diabetes, des troubles cardio-vasculaires et permettant de diminuer le risque des effets indesirables de la therapie de remplacement d'hormones
EP2124980A1 (fr) Composition d'extraits de trachelospermi caulis et de pyrola japonica pour la prévention et le traitement de maladies inflammatoires
WO2001085744A1 (fr) Compositions immunostimulantes et methodes associees
JP7350304B2 (ja) アレルギー性の鼻炎症状抑制剤
TWI442920B (zh) 香椿萃取物於減少體重或以降低體脂肪之藥物上之用途
JP3161882B2 (ja) 丹参由来多糖類、その製造法および用途
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
CN119185417B (zh) 活血降浊防心梗的组合物及其制备方法和应用
WO1996036346A1 (fr) Extrait hydrosoluble tire de la celosie argentee
JP2021512998A (ja) 分離された白茅根多糖及びその用途
JPH0748265A (ja) ネフローゼ症候群及び肝障害症状の寛解剤
CN105640792A (zh) 二氢杨梅素在美容除斑产品中的应用
CN105920046B (zh) 一种极性糖脂提取物及其应用
CN120983519A (zh) 一种益心丸的制备方法和应用
ITRM960279A1 (it) Uso di integratore dietetico comprendente chitosano, idrossicitrato di garcinia, cambogia e cromo organico nel trattamento della dislipi=

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase